P2RY12 and atrial fibrillation: In the MATRIX-2 trial [30], 3010 AF patients who have undergone successful PCI are being randomized to P2Y12 inhibitor monotherapy (clopidogrel, ticagrelor, or prasugrel) or standard of care therapy (i.e., initial and short TAT followed by 6–12 months of DAT) for the first month post-procedure, to be then switched to DOAC monotherapy for the following 11 months.